PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.49%
R&D reduction while AVXL shows 20.44% growth. Joel Greenblatt would examine competitive risk.
-16.18%
G&A reduction while AVXL shows 6.56% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
7.12%
Other expenses change of 7.12% while AVXL maintains costs. Bruce Berkowitz would investigate efficiency.
-22.68%
Operating expenses reduction while AVXL shows 15.70% growth. Joel Greenblatt would examine advantage.
-22.68%
Total costs reduction while AVXL shows 15.70% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
7.12%
D&A growth less than half of AVXL's 253.08%. David Dodd would verify if efficiency is sustainable.
22.73%
EBITDA growth while AVXL declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
22.68%
Operating income growth while AVXL declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
26.92%
Other expenses growth while AVXL reduces costs. John Neff would investigate differences.
22.99%
Pre-tax income growth while AVXL declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Tax expense growth 50-75% of AVXL's 196.24%. Bruce Berkowitz would examine efficiency.
22.99%
Net income growth while AVXL declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
38.32%
EPS growth while AVXL declines. John Neff would investigate advantages.
38.32%
Diluted EPS growth while AVXL declines. John Neff would investigate advantages.
24.80%
Share count reduction below 50% of AVXL's 1.51%. Michael Burry would check for concerns.
24.80%
Diluted share reduction below 50% of AVXL's 1.51%. Michael Burry would check for concerns.